Turning an old GADDget into a troublemaker by Capece, Daria et al.
  
 
Turning an old GADDget into a troublemaker 
Capece, D., D'Andrea, D., Verzella, D., Tornatore, L., Begalli, F., 
Bennett, J., Zazzeroni, F. & Franzoso, G. 
 
Published PDF deposited in Coventry University’s Repository  
 
Original citation:  
Capece, D, D'Andrea, D, Verzella, D, Tornatore, L, Begalli, F, Bennett, J, Zazzeroni, F & 
Franzoso, G 2018, 'Turning an old GADDget into a troublemaker' Cell Death & 




DOI    10.1038/s41418-018-0087-6 
ISSN   1350-9047 
ESSN  1476-5403 
 
 
Publisher: Springer Nature [academic journals on nature.com] 
 
 
Open Access This article is licensed under a Creative Commons Attribution 4.0 
International License, which permits use, sharing, adaptation, distribution and 
reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made. The images or other third party material in this article are 
included in the article’s Creative Commons license, unless indicated otherwise in a credit 
line to the material. If material is not included in the article’s Creative Commons license 
and your intended use is not permitted by statutory regulation or exceeds the permitted 
use, you will need to obtain permission directly from the copyright holder. To view a copy 
of this license, visit http://creativecommons.org/licenses/by/4.0/. 
 
Copyright © and Moral Rights are retained by the author(s) and/ or other copyright 
owners. A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. This item cannot be reproduced or quoted extensively 
from without first obtaining permission in writing from the copyright holder(s). The 
content must not be changed in any way or sold commercially in any format or medium 
without the formal permission of the copyright holders. 
Cell Death & Differentiation (2018) 25:640–642
https://doi.org/10.1038/s41418-018-0087-6
COMMENT
Turning an old GADDget into a troublemaker
Daria Capece1 ● Daniel D’Andrea1 ● Daniela Verzella1 ● Laura Tornatore1 ● Federica Begalli1 ● Jason Bennett1 ●
Francesca Zazzeroni2 ● Guido Franzoso1
Received: 31 January 2018 / Revised: 6 February 2018 / Accepted: 8 February 2018 / Published online: 6 March 2018
© The Author(s) 2018. This article is published with open access
Life must continually defend against infection. One of the
most ancient types of immunity is the process of active cell
death, which ﬁrst arose in evolution plausibly with protists,
as a primordial defence against intracellular parasites.
Owing to this common ancestral origin, there is remarkable
symmetry and overlap in proteins, signalling complexes and
domains between the pathways of apoptosis and those of
inﬂammation. The clearest paradigms of this interconnec-
tion and overlap are caspase-family proteases, which can
signal to cell death or the activation of proinﬂammatory
cytokines, and NF-κB-family transcription factors, the
ubiquitous rapid-response system centrally involved in the
regulation of apoptosis and immune and inﬂammatory
responses, in both vertebrates and invertebrates [1].
Given their central role in disease pathogenesis, the
mechanisms underpinning these pathways are of paramount
clinical signiﬁcance. Notably, in many cancer types, the
normally tight regulation of apoptosis and inﬂammation is
frequently disrupted by an aberrant NF-κB activation [2].
While multiple control mechanisms normally ensure the
prompt cessation of physiological NF-κB signalling, in
most human cancers, numerous alterations constitutively
activate NF-κB, enabling it to fuel tumour progression,
metastatic dissemination and therapy resistance by regulat-
ing genes that suppress cancer-cell apoptosis and orches-
trate inﬂammation in the tumour microenvironment (TME),
thus hijacking the ancient connection between apoptotic and
inﬂammatory pathways [2, 3].
Despite intense investigation, the mechanisms by which
NF-κB mediates these functions in oncogenesis remain
incompletely understood. Recently, we furthered their
understanding in multiple myeloma, a cancer where plasma
cells become addicted to NF-κB activation for survival. We
showed that oncogenic NF-κB signalling mediates this
effect by upregulating its pro-survival target gene,
GADD45B, a member of the GADD45-gene family. Con-
sequently, GADD45β is highly expressed in most multiple
myelomas, where it suppresses apoptosis ensuing from
spontaneous JNK/MAPK-pathway activation by inhibiting
the JNK kinase, MKK7 [4].
In addition to blocking cancer-cell apoptosis, oncogenic
NF-κB signalling operates in the TME, thereby linking
cancer to inﬂammation [3]. NF-κB activation in non-
malignant tumour-associated cells, especially those of the
myeloid lineage, has been shown to enhance the production
of cytokines and other specialised effectors that promote
tumour-cell proliferation, tissue invasion and therapy
resistance, while suppressing anti-tumour immune respon-
ses [5]. However, the notion that NF-κB would mediate its
oncogenic functions in malignant cells and the TME via
entirely different gene sets, which either suppress apoptosis
or govern inﬂammation, is at odds with the overall archi-
tectural conservation and co-evolution of these processes.
Recently, we demonstrated that this is indeed not the
case [6]. We identiﬁed a dedicated axis of the NF-κB
pathway, mediated by GADD45β, which integrates the NF-
κB-dependent mechanism suppressing tumour-cell apopto-
sis with that governing tumour-based inﬂammation [4, 6].
We showed that macrophage-associated GADD45β
expression governs an innate-immunity checkpoint
restricting TME-based inﬂammation and T-lymphocyte
trafﬁcking into tumours, the major barrier to effective
immunotherapy [6, 7]. Correspondingly, in animal models
of multiple solid cancers, myeloid-restricted Gadd45b
ablation restored pro-inﬂammatory tumour-associated
macrophage (TAM) activation and intratumoural immune-
cell inﬁltration, leading to TME-based tertiary lymphoid-
structure (TLS) formation, reactivation of anti-tumour
immune responses and diminished oncogenesis [6].
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Interestingly, GADD45β mediates these diverse oncogenic
functions through distinct mechanisms, which suppress
cancer-cell apoptosis by inhibiting MKK7/JNK activation
and curb inﬂammation by attenuating macrophage-
associated p38 signalling [4, 6].
From an evolutional perspective, it would seem advan-
tageous to unify anti-apoptotic and anti-inﬂammatory
pathways into an integrated mechanism relying on new
gene transcription, e.g. the GADD45β-mediated mechan-
ism, as a defence against intracellular pathogens such as
viruses. Such a mechanism would monitor the transcrip-
tional ﬁtness of the cell, as a cue that the cell is healthy or
has cleared the infection, and make it a prerequisite for cell
survival and, concurrently, terminating inﬂammation.
Conversely, if a virus has taken over the cellular biosyn-
thetic machinery to serve its reproductive needs, the same
mechanism would detect the infection and doom the cell to
die, while enabling the immune reaction to continue.
In keeping with this evolutional theme, GADD45 pro-
teins share homology with the L7Ae/L30e/S12e/GADD45
RNA-binding domain found in ribosomal and ribonucleo-
protein particle (RNP)-associated proteins in eukarya and
archaea [8, 9]. An ancient connection between ribosomes
and defence mechanisms is also suggested by the involve-
ment of ribosomal proteins in cell-death signalling and
immunity, and that of ribosomal protein S3 as a core sub-
unit of NF-κB complexes [10, 11]. This connection likely
stems from the integral involvement of ribosomes in both
viral replication and antiviral responses mediated by trans-
lation arrest and RNP aggregation into stress granules [12].
This raises new questions concerning the evolution and
biology of GADD45 proteins. For example, did they arise
as ribosomal components that later evolved into RNP-
associated defence mechanisms? Did their cap-independent
translation and role in DNA demethylation subsequently
arise as immune mechanisms capable of operating during an
infection [12, 13]?
Irrespective of when and how the different GADD45β
functionalities ﬁrst arose in evolution or were controlled by
NF-κB, the integration of the mechanisms governing
apoptosis and inﬂammation by the NF-κB/GADD45β axis
has far-reaching therapeutic implications. Indeed, despite
the long-lasting effort, developing a clinically useful NF-κB
inhibitor has not proven possible, due to the dose-limiting
toxicities of globally suppressing NF-κB [3, 14, 15].
We sought to overcome this problem in multiple mye-
loma by alternatively targeting the GADD45β/
MKK7 signalling module in a non-redundant, cancer-
restricted survival axis of the NF-κB pathway. We
demonstrated that GADD45β/MKK7-targeting agents are
effective in killing multiple myeloma cells, ex vivo and
in vivo, and, crucially, are not toxic to healthy tissues, as
they preserve the physiological functions of NF-κB [4]. Due
to this cancer-selective mode of action, GADD45β/MKK7
Fig. 1 Schematic representation of the dual functions of GADD45β in
oncogenesis. GADD45β mediates its distinct oncogenic functions
through separate tissue-speciﬁc mechanisms, which promote cancer
cell survival by inhibiting sustained MKK7/JNK activation (left) and
suppress TME-based inﬂammation, pro-inﬂammatory TAM activation
and CD8+ T-cell recruitment into tumours by attenuating
p38 signalling in myeloid cells (right). Also shown is how GADD45β-
targeting therapeutic agents could provide an effective means of
countering oncogenesis by promoting TME-based inﬂammation and
adaptive anti-tumour immune responses (right) and, at the same time,
inducing malignant cell apoptosis (left), thus affording a dual clinical
beneﬁt.
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inhibitors demonstrated no adverse effects, alongside a
cancer-selective pharmacodynamic response, in their ﬁrst-
in-human study in refractory multiple myeloma patients.
Notably, our ﬁnding that GADD45β also mediates a TME-
based innate-immunity checkpoint provides an attractive
therapeutic route downstream of NF-κB to reactivate anti-
tumour immune responses.
Indeed, while immunotherapies are revolutionising the
clinical management of certain malignancies, the majority of
cancer patients fails to respond to these therapies, due to
additional TME-mediated mechanisms that exclude T cells
from tumours or cause T-cell exhaustion [7]. An attractive
approach to overcome this barrier would be to reactivate TME-
based innate immunity. While no NF-κB inhibitor is clinically
approved for this purpose, the encouraging results from the
ﬁrst-in-human study of GADD45β/MKK7 inhibitors suggest
that the myeloid-associated GADD45β-dependent checkpoint
will be similarly amenable to therapeutic intervention for re-
programming TAMs to unleash TME-based inﬂammation and
redirect CD8+ T-cell trafﬁcking into tumours. Therefore,
innate immunotherapies targeting GADD45β could plausibly
overcome immunotherapy resistance, increasing response rates
in otherwise refractory cancer patients.
Further studies will determine the clinical beneﬁt of
combining conventional and GADD45β-targeting immu-
notherapies. This notwithstanding, our ﬁndings suggest that
targeting the NF-κB pathway through GADD45β would
provide an effective means to counter oncogenesis by
reversing TME-mediated immunosuppression and, con-
currently, inducing cancer-cell apoptosis, thereby providing
dual therapeutic beneﬁt (Fig. 1). The widespread correlation
between GADD45B expression and poor clinical outcome in
human cancers underscore the general clinical signiﬁcance of
the NF-κB-dependent mechanisms mediated by GADD45β
in oncogenesis [4, 6]. Only time will tell whether the ther-
apeutic opportunity presented by the GADD45β-mediated
signalling axis will turn out to be gold or just ﬂashes in the
pan. What is certain, though, is that disentangling the com-
plex mechanisms and networks underpinning the role of NF-
κB in oncogenesis will move the ﬁeld closer to seizing the
treasure trove of treatments still hidden in the NF-κB path-
way and ultimately solve its biology.
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